These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35225110)

  • 1. Optimizing cardio, hepato and phospholipidosis toxicity of the Bedaquiline by chemoinformatics and molecular modelling approach.
    Girase R; Ahmad I; Pawara R; Patel H
    SAR QSAR Environ Res; 2022 Mar; 33(3):215-235. PubMed ID: 35225110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.
    Patel H; Pawara R; Pawara K; Ahmed F; Shirkhedkar A; Surana S
    Tuberculosis (Edinb); 2019 Jul; 117():79-84. PubMed ID: 31378273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors.
    Ahmad I; Jadhav H; Shinde Y; Jagtap V; Girase R; Patel H
    In Silico Pharmacol; 2021; 9(1):23. PubMed ID: 33854869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure.
    Wu C; Luo J; Wu M; Meng F; Cai Z; Chen Y; Sun T
    Med Chem; 2020; 16(5):703-714. PubMed ID: 31203803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Anti-tubercular Analogues of Bedaquiline with Modified A-, B- and C-Ring Subunits.
    Barbaro L; Nagalingam G; Triccas JA; Tan L; West NP; Priebbenow DL; Baell JB
    ChemMedChem; 2023 Jan; 18(1):e202200533. PubMed ID: 36259365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Simplification of Bedaquiline: the Discovery of 3-(4-(N,N-Dimethylaminomethyl)phenyl)quinoline-Derived Antitubercular Lead Compounds.
    He C; Preiss L; Wang B; Fu L; Wen H; Zhang X; Cui H; Meier T; Yin D
    ChemMedChem; 2017 Jan; 12(2):106-119. PubMed ID: 27792278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of tuberculosis: Focus on bedaquiline.
    Chan B; Khadem TM; Brown J
    Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Chemical Property Position of Bedaquiline Construed by a Chemical Global Positioning System-Natural Product.
    Alajlani MM
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.
    Guo H; Courbon GM; Bueler SA; Mai J; Liu J; Rubinstein JL
    Nature; 2021 Jan; 589(7840):143-147. PubMed ID: 33299175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876-A Less Toxic and More Potent Analogue of Bedaquiline.
    Choi PJ; Conole D; Sutherland HS; Blaser A; Tong AST; Cooper CB; Upton AM; Palmer BD; Denny WA
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32245020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.
    Sutherland HS; Tong AST; Choi PJ; Blaser A; Conole D; Franzblau SG; Lotlikar MU; Cooper CB; Upton AM; Denny WA; Palmer BD
    Bioorg Med Chem; 2019 Apr; 27(7):1292-1307. PubMed ID: 30803745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines.
    Saxena AK; Alam M
    Curr Top Med Chem; 2020; 20(29):2723-2734. PubMed ID: 32885753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB.
    Svensson EM; Karlsson MO
    J Antimicrob Chemother; 2017 Dec; 72(12):3398-3405. PubMed ID: 28961790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
    Salifu EY; Agoni C; Olotu FA; Soliman MES
    Comput Biol Chem; 2020 Apr; 85():107204. PubMed ID: 31981966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
    Divita KM; Khatik GL
    Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of
    Sarathy JP; Ragunathan P; Shin J; Cooper CB; Upton AM; Grüber G; Dick T
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic approaches towards bedaquiline and its derivatives.
    Calvert MB; Furkert DP; Cooper CB; Brimble MA
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127172. PubMed ID: 32291133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.